Celgene launches new psoriasis drug Otezla in UK

Celgene has announced the UK launch of Otezla, a new oral therapy option for adult patients with psoriasis.

The drug is approved in Europe for the treatment of moderate to severe chronic plaque psoriasis in patients who cannot use phototherapy or other systemic treatments, or those who have tried these treatments without success.

It is also licensed for the treatment of the psoriasis-associated joint condition psoriatic arthritis among patients who cannot use or have failed to respond to disease-modifying antirheumatic drugs.

This therapy works by reducing the activity of an enzyme called phosphodiesterase 4, which is involved in the process of inflammation. It has been shown to be effective and generally well-tolerated in previous studies.

Helen McAteer, chief executive of the Psoriasis Association, said: "Psoriasis can be a debilitating skin condition, which can have both a physical and mental impact. We welcome all new treatment options that can reduce the burden of the condition and help patients live life to the full."

This comes after Celgene received a recommendation from the Scottish Medicines Consortium for its pancreatic cancer treatment Abraxane earlier this month.